BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy. This report describes the survival of children with ALL in the United States using the most comprehensive and up-to-date cancer registry data. METHODS: Data from 37 state cancer registries that cover approximately 80% of the US population were used. Age-standardized survival up to 5 years was estimated for children aged 0-14 years who were diagnosed with ALL during 2 periods (2001-2003 and 2004-2009). RESULTS: In total, 17,500 children with ALL were included. The pooled age-standardized net survival estimates for all US registries combined were 95% at 1 year, 90% at 3 years, and 86% at 5 years for children diagnosed during 2001-2003, and 96%, 91%, and 88%, respectively 
INTRODUCTION
One of the great successes in medicine in the United States has been the increasing survival of children with cancer. In the past 50 years, 5-year survival from all cancers combined among children in the United States has increased from <60% to nearly 80%. 1 Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy worldwide, accounting for 20% to 30% of overall childhood cancer incidence. [2] [3] [4] [5] Before 1950, childhood ALL was uniformly fatal. 6 In the 1960s, 5-year survival for children with ALL in the United States was <10%. 7, 8 Since then, 5-year survival has dramatically improved, from 57% between 1975 and 1979 to 90% between 2003 and 2009. 2, 9 This increase in survival is consistent with stable incidence rates and decreasing mortality rates. [10] [11] [12] The progress made in childhood ALL survival in developed countries over the past 4 decades largely stems from clinical and public health-related cancer control efforts. These include increasing clinical trial enrollment, improved supportive care, and risk-directed therapy that optimizes the efficacy of existing antileukemic agents. 1, [13] [14] [15] [16] Pediatric cancer collaborative treatment groups, which have reported enrollment of over two-thirds of patients with childhood ALL over the past 2 decades, have designed randomized clinical trials that used risk-adaptive algorithms to adjust the intensity of treatment based on factors such as ALL subtype and chromosomal changes, age and white blood-cell count on diagnosis, presence of disease in the central nervous system, and persistence of residual disease during treatment. 8, 13, [17] [18] [19] In addition to improving relapse-free and overall survival, a risk-based approach has allowed clinicians to reduce toxicities that contribute to late complications and mortality. 17 Clinical trials and ensuing advances in risk-based therapy have contributed to the remarkable progress in improving clinical outcomes in the United States and other countries. 13, 14, 20 This success lies in contrast to 5-year survival below 40% in many developing countries, which largely result from abandonment of therapy and high treatment-related mortality. [21] [22] [23] Five-year net survival among children diagnosed with ALL previously was estimated at 85% or above in the United States, whereas it was still below 50% in several less wealthy countries participating in the worldwide cancer survival comparison of the CONCORD-2 study. 2, 9 That study established worldwide surveillance of cancer survival in 67 countries using data from over 25 million individuals diagnosed with cancer from 279 cancer registries. 9 The current report builds on the CONCORD-2 study and describes the survival of children with ALL in the United States using the most comprehensive and up-to-date cancer registry data available by race and age.
MATERIALS AND METHODS
We used data from 37 state-wide cancer registries funded by the Centers for Disease Control and Prevention and the National Cancer Institute that participated in the CONCORD-2 study, covering approximately 80% of the US population, and consented to inclusion of their data in the more detailed analyses reported here. 9, 24, 25 We analyzed individual records for 17,500 children (ages 0-14 years) who were diagnosed with precursor-cell ALL (International Classification of Diseases for Oncology, third edition 26 morphology codes 9727-9729 and 9835-9837) during 2001 through 2009 and were followed until December 31, 2009 . We included all children with ALL in the analyses, even if the child had had a previous malignancy. In the extremely rare instance that a child was diagnosed with ALL on 2 or more occasions during 2001 through 2009, only the first occurrence was considered in the survival analyses.
We estimated net survival up to 5 years, with 95% confidence intervals (CIs), for children diagnosed during 2001 through 2003 and 2004 through 2009 by race and state. We used the Pohar Perme estimator 27 of net survival. Net survival can be interpreted as the probability of survival up to a given time since diagnosis after controlling for other causes of death (background mortality). To control for differences in background mortality between participating states by race and over time, we constructed life tables of all-cause mortality in the general population for each state from the number of deaths and the population, by single year of age, sex, calendar year, and, where possible, by race (black, white), using a flexible Poisson model. 28 The life tables have been published. 29 Children were grouped by diagnosis year into 2 calendar periods (2001-2003 and 2004-2009) We estimated net survival using the cohort approach for patients diagnosed during 2001 through 2003, because all patients had been followed for at least 5 years by December 31, 2009 . We used the complete approach to estimate 5-year net survival for patients diagnosed during 2004 through 2009, because 5 years of follow-up data were not available for all patients. Net survival was estimated for 4 age groups (ages <1 year and 1-4, 5-9, and 10-14 years). We obtained age-standardized estimates by assigning equal weights to 3 age-specific estimates (0-4, 5-9, and 10-14 years). 30 If 2 of the 3 age-specific estimates could not be obtained, then we present only the pooled, unstandardized survival estimate for all age groups combined (ages 0-14 years). Unstandardized estimates are italicized in Supporting Table 1 . To explore variation with age in more detail, the first age group was split into 2 subgroups (Table 1) . Trends, geographic variations, and differences in survival by race are presented graphically in bar charts and funnel plots. 31 More details on data and methods are provided in the accompanying article by Allemani et al. 32 
RESULTS
Data meeting the eligibility criteria for analyses came from 37 states comprising 80% of the total US population ( Table 2) . Of the 17,500 children with ALL, 83.7% were white, 8.9% were black, and 7.4% were of other or unknown race. Almost all cases (98.5%) were morphologically verified (Table 2 ). There were no differences in morphologic verification by race. (Table 1) . Survival was highest among children aged 1 to 4 years and lowest among those aged <1 year, with a 30% difference between these age groups in both periods. Survival was consistently slightly higher in girls than in boys, with the largest differences observed in infants aged <1 year throughout 2001 through 2009.
Funnel plots (Fig. 2) illustrate the variation in survival between states and by race. Five-year age-standardized These 5-year survival estimates from a population-based US cohort are slightly lower but still closely aligned with the 5-year survival estimates of 91.4% from the Children's Oncology Group ALL randomized trials for a similar period (2000) (2001) (2002) (2003) (2004) (2005) and the same age group. 8 Our results are also within the same range as most countries in Northern and Central Europe 5, 9 and close to those in Canada (90.6%; 95% CI, 88.6%-92.7%) for 2005 through 2009. 9 Our results are consistent with stable incidence rates and decreasing mortality rates for childhood ALL in the United States. [10] [11] [12] Despite the high overall survival, there were geographic and racial disparities. One-year survival for children diagnosed during 2004-2009 ranged from 91.4% to 98.9% in the Northeast. Differences in 5-year survival were even larger, ranging from 81.7% to 98.6% (see Supporting Table 1 ). Racial disparities were larger for longer-term survival than for shorterterm survival.
Five-year survival for black children was typically 3% to 5% lower than that for white children. Geographic differences in survival may be explained in part by survival differences between white and black children. Survival is generally lower for black children, and the proportion of black children varies by state. However, we observed that survival for black children was similar to, if not higher than, that of white children in some states (Supporting Table 1 ). This suggests that the distribution of black and white children does not explain all of the geographic differences in survival. Although genetic polymorphisms may partially explain racial differences in ALL outcomes, 33 these differences are more likely to be the reflection of differences in socioeconomic status and access to care. 34, 35 The survival patterns we observed by race are consistent with higher incidence rates among white children and higher mortality rates among black children. [10] [11] [12] The patterns of survival by age at diagnosis are consistent with other data from the United States 36 and other countries. 37 The survival of infants diagnosed with ALL is markedly lower than that for any other age group, which reflects the higher proportion in this age group of children diagnosed with ALL whose profile shows mixed-lineage leukemia gene rearrangements. 1 This population-based study confirms previous findings that the highest survival is found among children ages 1 to 4 years, with decreasing survival as age increases toward adolescence. 36 Biologic features of childhood leukemia that vary by age and have prognostic implications, such as the DNA index and specific chromosomal rearrangements, may explain differences in survival by age group. The current finding that survival differences in race were most pronounced at age <1 year or >4 years needs further study. 37 We also observed that, as previously reported, 38 boys have lower survival from ALL than girls. This sex difference was more marked in infants, for whom survival was the lowest, and it remained in the most recent period (2004-2009).
Five-year survival for patients with ALL in the United States is among the highest in the world, and it improved from 83.1% to 87.7% between 1995 and 2009, as reported by the CONCORD-2 study. 9 The high survival may reflect in part the intensity of clinical investigations performed to establish the diagnosis, which would be expected to improve the definition of morphologic type and thus the selection of the most appropriate treatment. One indicator of the intensity of diagnosis is the percentage of cases for which microscopic confirmation of the diagnosis was available. For children diagnosed with ALL during the period from 1995 through 2009 covered 
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Cancer December 15, 2017 by the CONCORD-2 study, morphologic verification was available for 98.4% of patients among all US registries combined and ranged between 85.6% and 100% among participating states. 9 Morphologic verification, as reported here, was similar among both black and white children diagnosed during 2001 through 2009. The low percentage of cases for which the diagnosis was based on clinical rather than pathologic evidence is not likely to be the result of selective case ascertainment among participating cancer registries, because all registries were certified by the North American Association of Central Cancer Registries as having met data quality and completeness standards.
Clinical Perspective
Important advances in childhood ALL survival have been achieved through both clinical and public health efforts. Clinical advances include improved supportive care and recognition of avenues to reduce the toxicity of therapy without compromising overall outcome. These advances in childhood ALL survival have spanned all age groups, races, and both sexes. 36 Clinicians have had increased success with managing the frequent complications of ALL, including tumor lysis syndrome, infection during neutropenia, thrombosis, hemorrhage, anaphylaxis, and suppression of the hypothalamic-pituitaryadrenal axis. [39] [40] [41] In addition, intrathecal therapy has been used increasingly instead of cranial irradiation for patients with central nervous system disease, thereby reducing radiation-associated morbidity and mortality. 33, 42 There has been increasing use of immunophenotyping and cytogenetic characterization to predict outcome and relapse and thus to guide risk-based adjustments in therapy. 6, 17 Advanced genetic characterization of ALL can contribute to improved diagnostic evaluation and enhance clinicians' ability to monitor the response to therapy. 17, 43 In addition, recent genotyping techniques have allowed clinicians to detect germ-line differences that may predict response to therapy, as well as chemotherapy-related side effects. 33 
Cancer Control Perspective
Many of these clinical advances have been achieved in conjunction with public health-related cancer control efforts, including support for clinical trial enrollment. 1 Sustained efforts by comprehensive cancer control programs to support clinical trial enrollment for children with cancer are needed to improve survival even further for children with ALL. With survival increasing, cancer control efforts must also focus on the long-term health of childhood ALL survivors. 20 Treatment of ALL may result in long-term health effects that may adversely affect the long-term health of childhood cancer survivors. Comprehensive cancer control programs could encourage the adoption of survivorship care plans and support efforts to improve providers' knowledge of established follow-up guidelines, such as the Children's Oncology Group longterm follow-up guidelines. 44 More widespread implementation of these guidelines could help improve and harmonize providers' knowledge of potential late effects, screening, evaluation, anticipatory guidance, counseling, and other interventions. 44 Comprehensive cancer control programs can also support efforts to reduce disparities among children with ALL. Although there were negligible differences in 1-year survival by race, we observed that black children had lower 5-year survival than white children. This likely reflects differences in access to treatment and may be related to socioeconomic status. [45] [46] [47] Cancer control efforts that increase access to care among families with lower socioeconomic status may help to reduce racial discrepancies in treatment and outcomes.
Limitations
This study did not include young persons aged 15 to 19 years, because it used the framework of the CONCORD-2 study, which used the conventional age range of 0-14 years for children in international cancer studies. Because many previous reports include individuals aged 15 years in their definition of childhood leukemia, comparing this study with past studies must account for differences in study population age. 2, 3, 10 Records of children diagnosed with leukemia were selected for analysis if their International Classification of Diseases for Oncology, third edition, morphologic code was 1 of the 6 codes proposed by the HAEMACARE Group for ALL. 48, 49 Although ALL is the most common childhood malignancy worldwide, absolute case numbers are generally small, and caution is needed in interpreting the data. Survival was estimated separately for each state, and estimates covering approximately 80% of the US population were also obtained by pooling the data from all participating states. Survival estimates could not be agestandardized for the less populous states, because the data were sparse. This limitation applies particularly to the comparison of survival between blacks and whites; because, in most states, black children represent fewer than 20% of ALL cases.
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Conclusions
Survival from childhood ALL has been improving overall in 37 US states between the periods 2001-2003 and 2004-2009 . Because of the relative rarity of childhood ALL, national and international collaboration groups that pool patient numbers and coordinate multicenter research efforts are essential. 13 Continued collaboration will be critical in reducing the persistent inequalities in survival from childhood ALL as well as in advancing treatment for childhood ALL. Similar research efforts will continue to play a central role in improving outcomes in other childhood cancers, for which survival is still well below 90%. Comprehensive cancer control programs can support efforts to increase clinical trial enrollment and providers' knowledge of established follow-up guidelines and to encourage the use of survivorship care plans. Close monitoring of survivors of childhood ALL using population-based cancer registry data are essential to monitor the effect of the implementation of new medical and public health strategies aimed at improving survival. 
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